The Deal

DECEMBER 19, 2023

“A profound change we have seen in the capital markets over the past few years has been the rise in interest rates, rising cost of capital, and what that’s led to is corporate boards and management teams reassessing effectively what they are the optimal owners of,” Dubner said.

Corporation 72

Corporation Capital Market Public Trading Healthcare 72

Lake Country Advisors

AUGUST 8, 2024

Market Capitalization Market capitalization is one of the simplest and most commonly used methods for valuing a publicly traded company. This metric provides a quick snapshot of a company’s total equity value as perceived by the stock market.

Valuation 97

Valuation Discounted Cash Flow S&P DCF Analysis 97

Cooley M&A

JANUARY 25, 2023

Will 2023 see a resurgence of traditional public M&A deals or will macro factors and the looming threat of regulatory review continue to push biotechnology companies down creative paths? It’s a more challenging market environment right now than we’ve seen in many years,” said Charlie Kim , who co-chairs Cooley’s capital markets practice.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

OCTOBER 29, 2020

On September 24, Cooley M&A partner, Garth Osterman, moderated a webinar on the current trend in going public: SPACs! For example, SPAC sponsors may be subject to shorter lock-up periods if certain pricing triggers are met, or the target shareholders may be subject to a longer lock-up period to align with that of the SPAC sponsors.

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

JANUARY 20, 2022

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. In June, GlaxoSmithKline announced its plans to spin off its consumer healthcare business to focus on its pharmaceutical and vaccine businesses.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Convergence of tech and healthcare drives digital health deals As discussed in our 2022 Life Sciences M&A Year in Review blog post , decreased valuations and challenging capital markets also impacted healthcare companies last year, and digital health companies – health companies that build and sell technology – were no exception.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52